Can I read Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom on EtoBox?

Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom by Versteegen, Pauline (author);Valente Pinto, Marta (author);Barkoff, Alex M. (author);van Gageldonk, Pieter G.M. (author);van de Kassteele, Jan (author);van Houten, Marlies A. (author);Sanders, Elisabeth A.M. (author);de Groot, Ronald (author);Diavatopoulos, Dimitri A. (author);Bibi, Sagida (author);Luoto, Raakel (author);He, Qiushui (author);Buisman, Anne-Marie (author);Kelly, Dominic F. (author);Mertsola, Jussi (author);Berbers, Guy A.M. (author) is a Medicine article available to read on EtoBox.

What is Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom about?

## Background Pertussis can lead to serious disease and even death in infants. Older adults are more vulnerable to complications as well. In high-income countries, acellular pertussis vaccines are used for priming vaccination. In the administration of booster vaccinations to different age groups and target populations there is a substantial between-country variation. We investigated the effect of age on the response to acellular pertussis booster vaccination in three European countries. ## Methods This phase IV longitudinal intervention study performed in Finland, the Netherlands and the United Kingdom between October 2017 and January 2019 compared the vaccine responses between healthy participants of four age groups: children (7–10y), adolescents (11–15y), young adults (20–34y), and older adults (60–70y). All participants received a three-component acellular pertussis vaccine. Serum IgG and IgA antibody concentrations to pertussis antigens at day 0, 28, and 1 year were measured with a multiplex immunoassay, using pertussis toxin concentrations at day 28 as primary outcome. This trial is registered with ClinicalTrialsRegister.eu (2016–003,678–42). ## Findings Children (__n__ = 109)

Who reads Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom?

Author

Versteegen, Pauline (author);Valente Pinto, Marta (author);Barkoff, Alex M. (author);van Gageldonk, Pieter G.M. (author);van de Kassteele, Jan (author);van Houten, Marlies A. (author);Sanders, Elisabeth A.M. (author);de Groot, Ronald (author);Diavatopoulos, Dimitri A. (author);Bibi, Sagida (author);Luoto, Raakel (author);He, Qiushui (author);Buisman, Anne-Marie (author);Kelly, Dominic F. (author);Mertsola, Jussi (author);Berbers, Guy A.M. (author)

Publisher

Elsevier BV

Published

2021

Language

EN

Field

Medicine (Life Sciences)